Viewing Study NCT00520767


Ignite Creation Date: 2025-12-25 @ 12:53 AM
Ignite Modification Date: 2026-06-18 @ 3:59 PM
Study NCT ID: NCT00520767
Status: COMPLETED
Last Update Posted: 2023-12-22
First Post: 2007-08-24
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Sponsor: Barbara Ann Karmanos Cancer Institute
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Systemic Amyloidosis View
None Light Chain Deposition Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None primary systemic amyloidosis View
None light chain deposition disease View